Last updated: May 29, 2026
LIDODERM (lidocaine) Suppliers: Contract Manufacturers, Raw-Material Vendors, and Supply-Chain IP Risks
Executive summary. LIDODERM (lidocaine 5% patch) is marketed in the U.S. by Endo Pharmaceuticals (brand ownership) and manufactured under contract/operations tied to licensed patch manufacturing capability and lidocaine supply chains. Public, document-level supplier granularity (named raw-material vendors for lidocaine and named contract manufacturing sites) is not fully exposed in standard public sources without pulling the specific FDA facility listings and current CMC exhibits for the active AND all approved manufacturing changes. As a result, a complete, source-backed “named supplier roster” cannot be produced from the information provided.
Which companies supply lidocaine for LIDODERM patch manufacturing?
Featured snippet answer. LIDODERM’s upstream input is lidocaine (API), plus patch-forming excipients and backing/liner materials. In the U.S., lidocaine API and intermediates are typically sourced through global small-molecule ingredient networks. Public-facing, brand-specific supplier names are usually not disclosed in FDA labeling or Orange Book entries.
How is lidocaine API sourced in topical patch supply chains?
- API-grade lidocaine is supplied by specialty generic API producers and chemical manufacturers with regulatory documentation (DMFs/ASMFs) and quality systems.
- Patch supply chains also require controlled-spec raw materials for:
- adhesive matrix systems
- backing films (polymeric layers)
- release liners
- packaging components that preserve strip integrity
Where do supplier names appear in FDA filings?
- DMF/ASMF referenced in FDA reviews often lists API manufacturers and authorized suppliers.
- CMC supplements list site-level manufacturing controls and any new suppliers for drug product components when changes require comparability and regulatory filings.
- Without the specific filing docket extracts and current supplements, it is not possible to produce a reliable “company X supplies lidocaine to brand Y” list.
What contract manufacturing organizations (CMOs) make LIDODERM patches?
Featured snippet answer. LIDODERM is a drug product (topical patch) requiring specialized line steps: backing/liner handling, adhesive casting or coating, die-cutting/assembly, and packaging. The patch manufacturing site(s) are listed in FDA facility databases tied to the approved application. Named CMOs are not stated in Orange Book records and are often disclosed only in facility listings tied to the application’s manufacturing site.
What manufacturing steps drive CMO selection for lidocaine patches?
- Precision coating for consistent dose per patch
- Adhesive performance validation (tack, shear, residence time)
- Strips/units packaging stability testing
- Line qualification and change control for regulators
What document types identify the patch manufacturer?
- FDA “Drug Establishment Registration and Listing” records for the application’s manufacturing facility
- FDA inspection classifications for facilities manufacturing the drug product
- CMC supplements tied to manufacturing changes
What is the Orange Book status of LIDODERM and how does it affect supplier risk?
Featured snippet answer. LIDODERM appears in the FDA Orange Book as a listed drug with patent/exclusivity protection. Those records affect generics and licensing, but they do not enumerate supplier identities.
How Orange Book records interact with the supply chain
- Orange Book listings drive generic entry timing and Paragraph IV strategy.
- Supply chain decisions (API and CMO sourcing) are governed by:
- facility qualification
- regulatory filing commitments (site and process)
- raw material change control
Why patent status does not identify suppliers
- Patents typically cover formulations, methods, or improvements, not the names of chemical or patch manufacturing vendors.
- Supplier names sit in DMFs, CMC, and establishment listings, not the Orange Book.
Are biosimilar-style supplier constraints relevant to LIDODERM?
Featured snippet answer. No. LIDODERM is a small-molecule topical product (lidocaine), so biosimilar frameworks and biosimilar-specific supply chains do not apply.
What supplier constraints matter for small-molecule topical patches
- Raw-material quality for lidocaine and adhesive components
- Film/liner supply consistency to avoid dosing variability
- Stability and microbiological controls for final packaged product
When does LIDODERM exclusivity expire and when could supply widen?
Featured snippet answer. Exclusivity timelines affect generic and authorized generic entry, which can change market sourcing leverage. However, supplier identity is still governed by CMC and regulatory filings.
What typically changes as competition approaches
- Additional API sourcing options (alternate suppliers for lidocaine)
- More capacity in packaging and patch manufacturing
- Lower unit costs driven by broader supply availability
What formulation and process patents influence alternative manufacturing suppliers?
Featured snippet answer. Formulation and process IP can restrict “how” alternate manufacturers produce the same therapeutic patch, even if sourcing inputs is feasible. But supplier names still come from regulatory site listings, not patents.
Key IP categories that affect CMO switch feasibility
- Adhesive matrix composition patents
- Penetration/permeation enhancement patents
- Patch manufacturing process and coating/casting method patents
- Stability and packaging format patents
Which regulatory pathways and submissions change the approved manufacturer list for LIDODERM?
Featured snippet answer. For an approved drug product, approved changes to manufacturing sites or critical components are made via supplements to the NDA. These supplements update facility information and sometimes introduce new suppliers for drug substance or excipient components.
What submission types can add suppliers
- Manufacturing site changes (process and controls supplements)
- Changes in drug substance manufacturer with bridging/validation data
- Changes in component suppliers that impact specification or impurity profiles
How do FDA facility listings determine who supplies LIDODERM at the site level?
Featured snippet answer. FDA facility registration and listing records identify manufacturing establishments for the drug product and often list drug substance handling sites. Those records are the most direct public source for “which companies make it,” but the current dataset is not included here.
What you can infer from facility records
- Drug product manufacturing facility identifiers
- Registered roles: manufacturing, testing, repackaging
- Geography and inspection history at facility level
Key Takeaways
- LIDODERM’s supply chain includes lidocaine API plus specialized patch-formulation and manufacturing inputs.
- Public Orange Book records do not name suppliers or CMOs.
- FDA facility listings and DMF/CMC source documents are the primary places supplier identities appear, but those records are not provided in the prompt, so a complete named supplier roster cannot be produced from available information.
- Competitive and IP timelines can change purchasing leverage, but they do not inherently reveal upstream or CMO vendor identities.
FAQs
- How do I find the exact FDA manufacturing site for LIDODERM? Use FDA drug establishment registration and listing for the LIDODERM application and manufacturing role entries.
- Does the Orange Book list the company that supplies lidocaine API for LIDODERM? No, Orange Book listings do not enumerate supplier identities for API.
- What documents list lidocaine API suppliers for small-molecule drugs like LIDODERM? DMFs/ASMFs and NDA CMC supplements tied to drug substance changes.
- Can LIDODERM use multiple patch manufacturing sites without new clinical data? Often yes through comparability and regulatory change control, depending on the nature of the change.
- Do formulation patents block new CMO sourcing for LIDODERM? They can block or constrain implementation of specific process/formulation approaches, affecting feasibility of alternative manufacturing.
References
No sources were provided in the prompt, and no document-level FDA/Orange Book/DMF records were included to cite.
